Janney Montgomery Scott LLC decreased its position in shares of Morningstar, Inc. (NASDAQ:MORN – Free Report) by 23.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,528 shares of the business services provider’s stock after selling 754 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Morningstar were worth $794,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Hughes Financial Services LLC bought a new position in Morningstar during the 1st quarter worth approximately $25,000. MAI Capital Management boosted its stake in Morningstar by 37.8% during the 1st quarter. MAI Capital Management now owns 153 shares of the business services provider’s stock worth $46,000 after acquiring an additional 42 shares during the last quarter. Larson Financial Group LLC boosted its stake in Morningstar by 5,066.7% during the 1st quarter. Larson Financial Group LLC now owns 155 shares of the business services provider’s stock worth $46,000 after acquiring an additional 152 shares during the last quarter. Blue Trust Inc. boosted its stake in Morningstar by 172.3% during the 1st quarter. Blue Trust Inc. now owns 177 shares of the business services provider’s stock worth $53,000 after acquiring an additional 112 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Morningstar by 23.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 178 shares of the business services provider’s stock worth $53,000 after acquiring an additional 34 shares during the last quarter. Institutional investors own 57.02% of the company’s stock.
Morningstar Stock Performance
Shares of MORN stock opened at $219.68 on Thursday. The company’s fifty day simple moving average is $246.59 and its 200-day simple moving average is $277.12. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 0.52. The firm has a market cap of $9.27 billion, a PE ratio of 23.40 and a beta of 1.00. Morningstar, Inc. has a 12 month low of $218.88 and a 12 month high of $365.00.
Wall Street Analysts Forecast Growth
MORN has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Morningstar from a “buy” rating to a “hold” rating in a research note on Saturday, July 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Morningstar in a research note on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Morningstar currently has an average rating of “Moderate Buy” and an average target price of $355.00.
Read Our Latest Stock Report on MORN
Insider Activity at Morningstar
In other news, Chairman Joseph D. Mansueto sold 6,705 shares of the business’s stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $260.65, for a total value of $1,747,658.25. Following the sale, the chairman owned 9,312,836 shares of the company’s stock, valued at $2,427,390,703.40. The trade was a 0.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 85,500 shares of company stock valued at $22,341,957 over the last 90 days. Insiders own 36.20% of the company’s stock.
Morningstar Profile
Morningstar, Inc provides independent investment insights in the United States, Asia. Australia, Continental Europe, the United Kingdom, and internationally. The company operates in five segments: Morningstar Data and Analytics; PitchBook; Morningstar Wealth; Morningstar Credit; and Morningstar Retirement.
See Also
- Five stocks we like better than Morningstar
- Growth Stocks: What They Are, Examples and How to Invest
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How to Calculate Options Profits
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Are Penny Stocks a Good Fit for Your Portfolio?
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Morningstar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morningstar and related companies with MarketBeat.com's FREE daily email newsletter.